0001279569-15-001145.txt : 20150526 0001279569-15-001145.hdr.sgml : 20150525 20150526164819 ACCESSION NUMBER: 0001279569-15-001145 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20150526 FILED AS OF DATE: 20150526 DATE AS OF CHANGE: 20150526 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merus Labs International Inc. CENTRAL INDEX KEY: 0001031516 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30082 FILM NUMBER: 15889945 BUSINESS ADDRESS: STREET 1: 100 WELLINGTON ST. WEST STREET 2: SUITE 2110 P.O. BOX 151 CITY: TORONTO STATE: A6 ZIP: M5K 1H1 BUSINESS PHONE: 416 593-3701 MAIL ADDRESS: STREET 1: 100 WELLINGTON ST. WEST STREET 2: SUITE 2110 P.O. BOX 151 CITY: TORONTO STATE: A6 ZIP: M5K 1H1 FORMER COMPANY: FORMER CONFORMED NAME: ENVOY CAPITAL GROUP INC. DATE OF NAME CHANGE: 20090223 FORMER COMPANY: FORMER CONFORMED NAME: ENVOY COMMUNICATIONS GROUP INC DATE OF NAME CHANGE: 19970127 6-K 1 merus6k.htm FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2015

Commission File No. 000-30082

MERUS LABS INTERNATIONAL INC.
(Translation of registrant's name into English)

100 Wellington St. West, Suite 2110 P.O. Box 151
Toronto, ON M5K 1H1
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [ ] Form 40-F [X]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ]

SUBMITTED HEREWITH

Exhibits
99.1	News Release Dated May 26, 2015 - Merus Labs Appoints Frank Rotmann VP & Head of European Operations

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 26, 2015

MERUS LABS INTERNATIONAL INC.

/s/ Andrew Patient
_________________________________________
Andrew Patient
Chief Financial Officer

EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 26, 2015

Exhibit 99.1

Merus Labs Appoints Frank Rotmann VP & Head of European Operations

TORONTO, May 26, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce the appointment of Frank Rotmann as Vice President and Head of European Operations, effective today.

Based in Zurich, Switzerland, Mr. Rotmann has over 20 years of experience in the pharmaceutical industry. Most recently, he held the position of VP for Central Eastern Europe for Takeda Pharmaceuticals. Previously, Mr. Rotmann held both country and regional responsibilities with full P&L accountability and a strong record of transforming businesses to profitable growth.

Mr. Rotmann has also held European and US-based leadership roles at Eli Lilly, Sanofi, Altana and Nycomed and has a Master of Business and Engineering degree from the Karlsruhe Institute of Technology (KIT) in Germany.

"We are thrilled to welcome Frank to the Merus executive team," said Barry Fishman, Chief Executive Officer. "His deep knowledge of pharmaceutical lifecycle management and results-driven approach will be valuable assets to take our European business to the next level."

About Merus Labs International Inc.

Merus Labs is a specialty pharmaceutical company focused on acquiring established products. The Company leverages its expertise in European and North American markets to optimize the value of underdeveloped pharmaceutical assets.

Cautionary Statement

Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to complete future acquisitions and to integrate these acquisitions into its business, Merus' ability to complete future debt and/or equity financings required to complete future acquisitions, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus' plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

SOURCE Merus Labs International Inc.

%CIK: 0000030082

For further information: Merus Labs International Inc., Tel: (416) 593-3725, Or contact our investor relations department at: info@meruslabs.com

CO: Merus Labs International Inc.

CNW 11:23e 26-MAY-15